Neuroendocrine Tumors (NETs) Market was valued at USD 7.10 billion in 2024 and is projected to reach USD 16.25 billion by 2034

Market Overview
The Neuroendocrine Tumors (NETs) Market was valued at USD 7.10 billion in 2024 and is projected to reach USD 16.25 billion by 2034, growing at a CAGR of 8.7% during the forecast period.

Neuroendocrine tumors are a diverse group of malignancies arising from neuroendocrine cells, most commonly found in the gastrointestinal tract, pancreas, and lungs. NETs often present with slow progression but can become aggressive, requiring targeted therapies, radionuclide treatments, and multimodal approaches.

Growing incidence of NETs, rising use of advanced imaging and biomarkers, expansion of targeted therapy options, and increasing patient awareness are major contributors to market growth. The success of peptide receptor radionuclide therapy (PRRT), somatostatin analogs, and immunotherapies has significantly transformed the treatment landscape.

Download Full PDF Sample Copy of Market Report
https://exactitudeconsultancy.com/request-sample/71607

Market Dynamics
Drivers
• Rising global incidence of NETs due to improved detection and awareness.
• Increasing adoption of targeted therapies, including everolimus, sunitinib, and somatostatin analogs.
• Growing use of peptide receptor radionuclide therapy (PRRT) such as Lutathera.
• Advancements in diagnostic imaging like PET-CT, Ga-68 DOTATATE scans, and MRI.
• Expansion of oncology treatment centers and access to multidisciplinary care.

Restraints
• High cost of targeted therapies and PRRT, limiting access in some regions.
• Diagnostic delays due to nonspecific symptoms and disease variability.
• Limited treatment options for high-grade or poorly differentiated NETs.
• Side effects associated with long-term use of targeted drugs.
• Shortage of specialized nuclear medicine facilities in developing markets.

Opportunities
• Development of next-generation PRRT compounds and combination regimens.
• Increasing research in immunotherapy and CAR-T solutions for aggressive NETs.
• Growth in biomarker-driven personalized therapy.
• Expansion of artificial intelligence in NET imaging interpretation.
• Rising clinical trials exploring novel multi-target kinase inhibitors.

Market Growth Outlook (2024-2034)
The Neuroendocrine Tumors Market will grow from USD 7.10 billion in 2024 to USD 16.25 billion by 2034, driven by rising NET prevalence, advancements in molecular diagnostics, and expanding targeted therapy pipelines.
Future growth is expected to be shaped by PRRT innovation, AI-driven diagnostics, and personalized medicine strategies.

Explore Full Report here:
https://exactitudeconsultancy.com/reports/71607/neuroendocrine-tumors-nets-market

Segmentation Analysis
By Type of Tumor
• Gastrointestinal NETs (GI-NETs) - Most common, affecting stomach, small intestine, colon, and appendix.
• Pancreatic NETs (pNETs) - Includes functioning and non-functioning tumors, often requiring targeted therapy.
• Pulmonary NETs - Typical and atypical carcinoid tumors.
• Other NETs - Merkel cell carcinoma, thymic NETs, and rare anatomical presentations.

By Treatment Type
Somatostatin Analogs (SSAs):
• Octreotide, lanreotide widely used for symptom control and tumor growth inhibition.
Targeted Therapies:
• Everolimus (mTOR inhibitor) and sunitinib (TKI) for progressive NETs.
• Newer kinase inhibitors and multi-target compounds under development.

Peptide Receptor Radionuclide Therapy (PRRT):
• Lutathera (Lu-177) is transformative for somatostatin receptor-positive NETs.
Chemotherapy:
• Used primarily in high-grade and poorly differentiated NETs.
Immunotherapy:
• Investigational use of checkpoint inhibitors in selected advanced NET cases.
By Diagnosis
• Biochemical Testing: Chromogranin A, serotonin, 5-HIAA.
• Imaging: PET-CT (Ga-68 DOTATATE), CT, MRI, somatostatin receptor imaging.
• Biopsy & Histopathology: Ki-67 index and grading critical for prognosis.
• Genomic Profiling: Growing use in treatment selection.

By End User
• Hospitals & Oncology Centers providing multidisciplinary NET management.
• Nuclear Medicine Facilities delivering PRRT treatment.
• Diagnostic Imaging Centers specializing in NET scans.
• Research Institutes involved in drug and biomarker development.

Get Your Exclusive Offer with up to 10% Discount
https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=71607

Regional Insights
North America
North America leads the market due to high diagnostic rates, strong availability of PRRT, advanced oncology infrastructure, and significant adoption of targeted therapies. The U.S. dominates regional revenue.

Europe
Europe is a major market supported by established PRRT centers, high NET awareness, and strong reimbursement structures. Germany, Italy, France, and the UK are key contributors.

Asia Pacific
Asia Pacific is the fastest-growing region, driven by rising cancer incidence, expanding access to targeted therapies, and improving nuclear medicine capabilities in China, India, Japan, and South Korea.

Latin America & Middle East/Africa
Moderate growth due to limited advanced NET treatment infrastructure, though adoption is rising as oncology services expand.

Competitive Landscape
The NETs market includes biologics manufacturers, radionuclide therapy developers, and oncology therapy innovators.

Key Companies Include:
• Novartis (Lutathera, Sandostatin)
• Pfizer
• Ipsen (Somatuline Depot)
• Roche
• Bayer
• Merck
• AstraZeneca
• Thermo Fisher Scientific (diagnostics)
• GE Healthcare (imaging solutions)
• Advanced Accelerator Applications (PRRT technology)

These companies focus on expanding targeted therapy portfolios, improving radionuclide treatment access, and advancing diagnostic platforms.

Recent Developments
• Growing use of Lutathera PRRT for advanced NETs with continued expansion across new regions.
• Development of next-generation somatostatin analogs with longer action.
• Rising adoption of AI-based NET imaging tools improving tumor detection.
• Increasing clinical trials evaluating combination regimens (e.g., PRRT + targeted therapy).
• Advancements in liquid biopsy and biomarker discovery for early NET detection.

This report is also available in the following languages : Japanese (神経内分泌腫瘍(NET)市場), Korean (신경내분비종양(NET) 시장), Chinese (神经内分泌肿瘤(NETs)市场), French (Marché des tumeurs neuroendocrines (TNE)), German (Markt für neuroendokrine Tumore (NET)), and Italian (Mercato dei tumori neuroendocrini (NET)), etc.

Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @
https://exactitudeconsultancy.com/request-sample/71607

Our More Reports:

Limb Girdle Muscular Dystrophy (LGMD) Market
https://exactitudeconsultancy.com/reports/71657/limb-girdle-muscular-dystrophy-lgmd-market

Morquio Syndrome Market
https://exactitudeconsultancy.com/reports/71659/morquio-syndrome-market

Mucopolysaccharidosis II Market
https://exactitudeconsultancy.com/reports/71661/mucopolysaccharidosis-ii-market

Neurofibromatosis Type 1 Market
https://exactitudeconsultancy.com/reports/71663/neurofibromatosis-type-1-market

About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/

https://www.thehealthanalytics.com/

https://www.analytica.global/

https://www.marketintelligencedata.com/

https://www.marketinsightsreports.com/

https://exactitudeconsultancy.com/

Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com

This release was published on openPR.